Contents
Special Issue Topic

Molecular Mechanisms and Intervention Options in Metastatic Spread of Cancer

Submission Deadline: June 30, 2025

Guest Editor

Dr. Katrin Sak E-Mail

NGO Praeventio, Tartu, Estonia

About the Special lssue

Metastasis is the final and most devastating step in carcinogenesis, being the leading cause of cancer-related deaths. This multistep and complex process encompasses detachment of tumoral cells from the primary neoplasm, their migration and invasion through extracellular matrix, intravasation into bloodstream, survival within the circulation, extravasation and formation of secondary lesions in different distant sites. Despite the recent extensive research, there are still many unsolved aspects regarding molecular mechanisms of metastatic cascade, early detection of cancer spread as well as its targeting strategies. The availability of antimetastatic drugs is limited, while conventional therapeutic options, such as certain cytotoxic drugs, have been found to sometimes even promote the metastatic spread. Therefore, this special issue is devoted to the studies on all aspects of cancer metastasis to better understand its biological mechanisms and develop new efficient options for intervening in this multistep process. Both in vitro and in vivo studies as well as case reports and clinical trials focusing on novel antimetastatic agents, their cellular targets and action mechanisms are very welcomed to be submitted to this special issue. 

Keywords: Metastasis; cancer spread; migration; invasion; angiogenesis; molecular mechanisms; cellular signaling cascades; antimetastatic agents; novel anticancer therapies

Published Articles

Open Access Review
Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodulation
Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognostics and substantial therapeutic challenges, with dismal survival rates. Tumor resistance in PDAC is primarily attributed to i
Published: August 15, 2024 Explor Target Antitumor Ther. 2024;5:1056–1073
2167 40 2
Open Access Review
Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: a review of the recent phase III trials
Tumors with an impaired ability to repair DNA double-strand breaks by homologous recombination, including those with alterations in breast cancer 1 and 2 (BRCA1 and BRCA2) genes, are very sensitive
Published: August 02, 2024 Explor Target Antitumor Ther. 2024;5:997–1010
1216 33 1